Drug Profile
AZD 3102
Alternative Names: AZD-3102Latest Information Update: 15 Jan 2019
Price :
$50
*
At a glance
- Originator Dyax
- Developer AstraZeneca; Takeda
- Class Antidementias; Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 04 Nov 2017 No recent reports of development identified for preclinical development in Alzheimer's-disease in Europe (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA (Parenteral)